Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here